Trial Profile
Pazopanib NCRCC, Ph2 STUDY
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 24 Apr 2017 Status changed from active, no longer recruiting to completed.
- 21 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Aug 2015 as reported by the ClinicalTrials.gov record.
- 21 Jan 2014 Status changed from not yet recruiting to recruiting as reported by the ClinicalTrials.gov record.